Varicella – Diagnostics – Overview of Information and Clinical Research

Diagnosing chickenpox (varicella) is usually straightforward, as the characteristic itchy, blister-like rash often tells the story on its own. However, knowing when to seek medical advice, understanding the methods doctors use to confirm the infection, and learning about tests needed for specific situations can help you make informed decisions about care.

Introduction: Who Should Undergo Diagnostics and When to Seek Them

Most cases of chickenpox are identified without the need for complex medical testing. The disease announces itself through a distinctive pattern: an itchy rash that begins as small red bumps, progresses to fluid-filled blisters, and finally crusts over into scabs. For many families, especially those with children, this visual presentation is enough to recognize the infection and begin home care^[1].

However, not everyone should wait and watch. Certain individuals need to seek medical evaluation promptly when they suspect chickenpox exposure or notice symptoms developing. Pregnant women who have never had chickenpox or the vaccine should contact their healthcare provider immediately after exposure, as the virus can harm unborn babies and be life-threatening for newborns. People with weakened immune systems—such as those with HIV/AIDS, cancer patients, transplant recipients, or anyone taking medications that suppress immunity—also require urgent medical attention^[4].

Adults who develop chickenpox face higher risks of complications than children do. While children account for most chickenpox cases, adults make up approximately 35% of deaths related to the disease. This stark contrast means adults experiencing symptoms should not dismiss them as minor^[9].

⚠️ Important

Seek immediate medical care if you experience trouble breathing, severe headache with stiff neck, sensitivity to light, extreme drowsiness or confusion, eye pain or drainage, or if areas around chickenpox blisters become increasingly red, warm, swollen, or leak thick yellowish fluid. These signs may indicate serious complications requiring prompt treatment^[18].

Timing matters when deciding to seek diagnostics. The rash typically appears 10 to 21 days after exposure to the virus, with an average of about two weeks. During the one to two days before the rash emerges, some people experience fever, headache, tiredness, and loss of appetite. This is when the disease is already contagious, even though the telltale spots have not yet appeared^[1].

Children showing the classic symptoms usually do not need formal diagnostic testing. Parents can manage the illness at home with supportive care, keeping the child comfortable while the immune system fights the virus. However, if fever persists beyond four days, if the child develops a severe cough or has difficulty breathing, or if the rash shows signs of bacterial infection, medical evaluation becomes necessary^[11].

Classic Diagnostic Methods to Identify the Disease

The primary method for diagnosing chickenpox is clinical diagnosis, which means healthcare providers rely on observing the characteristic rash and hearing about symptoms. When a provider examines a patient with chickenpox, they look for specific features that distinguish this infection from other conditions. The rash typically starts on the chest, back, and face before spreading across the body. A distinctive feature is that blisters appear in different stages at the same time—some are just forming as red bumps, others have progressed to fluid-filled blisters, and still others have already crusted over into scabs. This “multiple stages at once” pattern is a hallmark of chickenpox^[7].

Healthcare providers also consider the distribution pattern of the rash. Chickenpox lesions tend to concentrate more heavily on the trunk (the chest and back) rather than the arms and legs. This is called a centripetal distribution, meaning the rash is denser toward the center of the body. The blisters can appear on the scalp, in the armpits, and even inside the mouth, on the eyelids, or in the genital area. Some children develop as few as a handful of blisters, while others may have 250 to 500 lesions covering their bodies^[9].

Since the introduction of widespread vaccination programs, chickenpox has become less familiar to many clinicians. Additionally, vaccinated individuals who develop “breakthrough” chickenpox may present with atypical rashes—milder cases with fewer blisters that may not follow the typical progression. These factors have made laboratory confirmation increasingly important, even though most straightforward cases still receive clinical diagnosis alone^[5].

When laboratory testing is needed, several methods are available. Polymerase chain reaction (PCR) testing has emerged as the preferred method for confirming chickenpox infection. PCR is the most sensitive and timely way to identify the varicella-zoster virus. To perform this test, healthcare providers collect a sample of fluid from a fresh blister or scrape cells from the base of a lesion. The laboratory then analyzes the sample for genetic material from the virus^[5].

Another testing method is direct fluorescent antibody assay (DFA), which is highly specific for detecting the virus but less sensitive than PCR. DFA involves taking a sample from skin lesions and using special antibodies that attach to viral proteins, making them visible under a fluorescent microscope. While this method is very accurate when it shows a positive result, it may miss some infections that PCR would detect^[5].

Viral culture represents another diagnostic option, though it is less commonly used today. In viral culture, healthcare providers collect fluid from blisters and place it in a special growth medium. If the varicella-zoster virus is present, it will multiply in this medium over several days, confirming the diagnosis. However, viral culture takes longer than PCR or DFA and is less sensitive, meaning it may not always detect the virus even when infection is present^[2].

Blood tests can also play a role in diagnosis, though they are typically used in specific situations rather than for routine cases. A test measuring IgG antibodies in paired blood samples—one taken during the acute illness and another during recovery—can confirm chickenpox if it shows a fourfold increase in antibody levels. This method has excellent specificity, meaning positive results are very reliable. However, sensitivity is lower, and vaccinated individuals may not show the expected antibody rise even when infected. For these reasons, blood antibody testing is less useful than direct viral detection methods^[5].

One type of blood test that is specifically not recommended is IgM antibody testing. While IgM antibodies are often associated with acute infections, tests for varicella-zoster IgM antibodies have proven unreliable for diagnosing chickenpox^[5].

Healthcare providers must also distinguish chickenpox from other conditions that cause similar rashes. Differential diagnosis—the process of determining which disease is causing symptoms—involves considering other possibilities. Conditions that might be confused with chickenpox include other viral infections causing rashes, bacterial skin infections, allergic reactions, insect bites, or even shingles. Shingles is caused by the same virus as chickenpox but typically appears as a painful rash limited to one area of the body, following the path of a nerve, rather than spreading across the entire body^[3].

Diagnostics for Clinical Trial Qualification

Clinical trials testing new treatments or prevention strategies for chickenpox require precise diagnostic criteria to ensure participants truly have the condition being studied. These standards are more rigorous than those used in everyday medical practice because research findings must be accurate and reliable. While the sources provided do not detail specific clinical trial enrollment criteria for varicella studies, we can understand that laboratory confirmation would be essential for research purposes^[5].

Researchers designing clinical trials must ensure all participants have been correctly diagnosed. This typically means laboratory testing would be required rather than relying solely on clinical observation. PCR testing, being the most sensitive and specific method available, would likely serve as the gold standard for confirming chickenpox infection in study participants. This ensures that everyone enrolled actually has the disease, preventing contamination of research results with individuals who might have similar-appearing conditions^[5].

Trials might also require documentation of vaccination history, previous chickenpox infection, or antibody testing to establish immune status before enrollment. Studies testing vaccines or preventive treatments would need to confirm that participants have never had chickenpox and lack immunity to the virus. Conversely, trials evaluating treatments for active infection would require confirmed cases through viral detection methods^[2].

Prognosis and Survival Rate

Prognosis

For most healthy children, chickenpox follows a predictable course with excellent outcomes. The illness typically lasts four to seven days, with the rash remaining active for about five to ten days before all blisters crust over and begin healing. Children usually miss five to six days of school or childcare but recover completely without lasting effects. The disease is generally mild in young children, causing discomfort from itching and fever but rarely leading to serious problems^[1].

The prognosis changes significantly based on age and immune status. Adults, adolescents, infants under one year old, and pregnant women face substantially higher risks of complications. While adults account for only about 5% of reported chickenpox cases, they represent approximately 35% of deaths related to the disease. Complications in these high-risk groups can include bacterial skin infections, pneumonia (either viral or secondary bacterial), inflammation of the brain (encephalitis), inflammation of the cerebellum causing balance problems (cerebellar ataxia), blood clotting disorders, and liver inflammation^[9].

People with weakened immune systems—such as those with HIV/AIDS, cancer patients, transplant recipients, or individuals taking immunosuppressive medications—face the greatest risk of severe disease. In these populations, chickenpox can become life-threatening, with the virus potentially spreading throughout the body and affecting multiple organs. Early treatment with antiviral medications is crucial for preventing dangerous complications in immunocompromised individuals^[1].

After recovering from chickenpox, most people develop lifelong immunity and will not get the disease again. However, the varicella-zoster virus does not leave the body. Instead, it becomes dormant (inactive) in nerve cells near the spine and can reactivate years or even decades later, causing shingles. About one in three people who had chickenpox will develop shingles at some point in their life, with risk increasing significantly after age 50. By age 85 and older, the risk of developing shingles reaches one in two^[8].

Vaccinated individuals who develop breakthrough chickenpox despite immunization typically experience much milder disease. These cases usually involve fewer than 50 skin lesions (compared to 250-500 in unvaccinated individuals), shorter duration of illness, lower or no fever, and faster recovery. The rash may also look different, appearing more as red bumps rather than progressing through the typical fluid-filled blister stage. Most importantly, the chickenpox vaccine prevents almost all cases of severe illness, meaning vaccinated individuals are protected from dangerous complications even if they do develop a mild case of chickenpox^[5].

Survival rate

Chickenpox is rarely fatal in otherwise healthy children. With modern medical care and the availability of antiviral treatments when needed, most people recover completely. However, the disease can be serious or even life-threatening in certain populations. Before the chickenpox vaccine became available in 1995, chickenpox caused approximately 10,500 to 13,000 hospitalizations and 100 to 150 deaths each year in the United States. Most deaths occurred in previously healthy children, though adults and immunocompromised individuals faced higher individual risk^[1].

Since the introduction of widespread vaccination programs, both the number of chickenpox cases and deaths have decreased dramatically. The vaccine has reduced chickenpox cases by approximately 97% and has greatly decreased hospitalizations and deaths. This represents one of the major public health successes of vaccination programs^[17].

The risk of complications varies significantly by age and immune status. Healthy children generally face minimal risk of serious problems. Adults, on the other hand, have much higher rates of complications including pneumonia, which occurs more frequently in this age group. Pregnant women who contract chickenpox, particularly during the first 20 weeks of pregnancy, face risks of complications both for themselves and their developing babies. Newborns whose mothers develop chickenpox shortly before or after delivery are at extremely high risk of severe, potentially fatal infection^[4].

#1 Clinical Trials Search in Europe